The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Risankizumab is effective through 2.5 years of treatment among patients with psoriasis, with most patients achieving rapid and sustained response.

In 2019, BMS made a big bet on Sotyktu by deciding to keep the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, BMS sold its mega-blockbuster Otezla to Amgen for ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

When you have psoriasis — a skin disease that typically causes thick, itchy, scaly, or discolored patches of skin — finding a treatment that works for you can be a challenge. Luckily, there are more ...

AJMC: Please describe the process for the treatment of psoriasis currently at your health system, Emory Healthcare. What guidelines/pathways are involved? HAUMSCHILD: Our psoriasis treatment approach ...

For many people living with psoriasis, the red, scaly skin patches are only part of the story. Another challenge is the uncertainty about whether there is anything they can do themselves to help ...

Can what you eat help calm psoriasis, a chronic inflammatory disease that affects the skin? It's identified by the development of thick, red patches with silvery scales, causing the area to itch or ...